Michael J. Thrall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael J. Thrall has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
Elizabeth Jenkins
American Society of Cytopathology, Wilmington, Delaware
5 shared publications- Momin T. Siddiqui
Department of Pathology and Laboratory Medicine, New York-Presbyterian Hospital-Weill Cornell Medicine, New York, New York
5 shared publications Susan Alperstein
Department of Pathology and Laboratory Medicine, New York Presbyterian-Weill Cornell Medicine, New York, New York
5 shared publications- Liron Pantanowitz
Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA
4 shared publications - Amber D. Donnelly
Diagnostic Cytology Education, University of Nebraska Medical Center, College of Allied Health Professions, Omaha, Nebraska
3 shared publications Anil V. Parwani
Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio
3 shared publications
Latest Publications
- 16 October 2024
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 14 (1) , 55-63
Tools, techniques, and challenges in preparing cytology specimens for ancillary studies: results of the ASC Optimizing Cytology and Small Biopsy Specimen Processing for Ancillary Studies task force survey
- 16 October 2024
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 14 (1) , 55-63
Tools, techniques, and challenges in preparing cytology specimens for ancillary studies: results of the ASC Optimizing Cytology and Small Biopsy Specimen Processing for Ancillary Studies task force survey
- Open Access
- 20 September 2024
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 14 (1) , 11-22
Triage options for positive high-risk HPV results from HPV-based cervical cancer screening: a review of the potential alternatives to Papanicolaou test cytology
- 20 September 2024
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 14 (1) , 11-22
Open AccessTriage options for positive high-risk HPV results from HPV-based cervical cancer screening: a review of the potential alternatives to Papanicolaou test cytology
- Open Access
- 16 April 2024
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 13 (5) , 319-328
The current state of digital cytology and artificial intelligence (AI): global survey results from the American Society of Cytopathology Digital Cytology Task Force
- 16 April 2024
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 13 (5) , 319-328
Open AccessThe current state of digital cytology and artificial intelligence (AI): global survey results from the American Society of Cytopathology Digital Cytology Task Force
- 9 December 2023
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 13 (2) , 111-121
American Society of Cytopathology Telecytology validation recommendations for rapid on-site evaluation (ROSE)
- 9 December 2023
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 13 (2) , 111-121
American Society of Cytopathology Telecytology validation recommendations for rapid on-site evaluation (ROSE)
- Top Cited Papers
- 2 December 2023
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 13 (2) , 97-110
Digital cytology part 2: artificial intelligence in cytology: a concept paper with review and recommendations from the American Society of Cytopathology Digital Cytology Task Force
- 2 December 2023
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 13 (2) , 97-110
Top Cited PapersDigital cytology part 2: artificial intelligence in cytology: a concept paper with review and recommendations from the American Society of Cytopathology Digital Cytology Task Force
- Open Access
- 10 November 2023
- Published by Wiley in Diagnostic Cytopathology
- Vol. 52 (2) , 82-92
A retrospective analysis of molecular testing in cytologically indeterminate thyroid nodules with histologic correlation: Experience at a heterogenous multihospital system
Introduction: Thyroid malignancy is one of the most common types of cancer in developed nations. Currently, fine‐needle aspiration cytology (FNAC) is the most practical screening test for thyroid nodules. However, cytologically indeterminate samples comprise approximately 15%–30% of cases. These include cases classified as atypia of undetermined significance (AUS), follicular neoplasm (FN), and suspicious for malignancy (SFM). Indeterminate cases can be sent for molecular testing for more definitive classification to help guide management and prevent overtreatment of benign thyroid nodules. We conducted a retrospective review on molecular testing of indeterminate thyroid FNAC and reviewed subsequent histologic diagnoses in resection specimens to assess how molecular testing supported a diagnosis and its effect on clinical management of patients at our institution.Methods: A retrospective chart review was performed on all thyroid FNAC specimens, corresponding molecular testing, and subsequent surgical resection specimens over a 6‐year period.Results: A total of 10,253 thyroid FNAC were performed in our hospital system during our study period, of which 10% (n = 1102/10,253) had indeterminate FNAC results. Molecular testing was performed in 16% (n = 178/1102) of indeterminate cytology cases. Genetic alterations were identified in 39% (n = 69/178) of the cases sent for molecular testing. The majority of cytologically indeterminate cases sent for molecular testing were follicular‐patterned lesions and their corresponding resection specimens revealed mostly low grade follicular derived neoplasms (i.e., follicular adenoma, non‐invasive follicular thyroid neoplasm with papillary‐like nuclear features, and follicular variant of papillary thyroid carcinoma). Of the cases with identified genetic alterations, 75% (n = 52/69) were treated surgically. In cases with no genetic alterations identified, only 18% (n = 20/109) were treated surgically.Discussion/Conclusion: Molecular testing on cytologically indeterminate thyroid nodules can help provide a more accurate risk of malignancy assessment in patients with lesions that are difficult to diagnosis based solely on FNAC morphology. The types of genetic alterations identified in the resected thyroid lesions were consistent with what has been previously described in the literature. Additionally, we found that in the patients with indeterminate thyroid FNAC with adjunct molecular testing, more than half did not undergo surgical resection. This finding emphasizes the value of adding molecular testing in patients, particularly when attempting to reduce unnecessary surgical intervention.
- 10 November 2023
- Published by Wiley in Diagnostic Cytopathology
- Vol. 52 (2) , 82-92
Open AccessA retrospective analysis of molecular testing in cytologically indeterminate thyroid nodules with histologic correlation: Experience at a heterogenous multihospital system
Introduction: Thyroid malignancy is one of the most common types of cancer in developed nations. Currently, fine‐needle aspiration cytology (FNAC) is the most practical screening test for thyroid nodules. However, cytologically indeterminate samples comprise approximately 15%–30% of cases. These include cases classified as atypia of undetermined significance (AUS), follicular neoplasm (FN), and suspicious for malignancy (SFM). Indeterminate cases can be sent for molecular testing for more definitive classification to help guide management and prevent overtreatment of benign thyroid nodules. We conducted a retrospective review on molecular testing of indeterminate thyroid FNAC and reviewed subsequent histologic diagnoses in resection specimens to assess how molecular testing supported a diagnosis and its effect on clinical management of patients at our institution.Methods: A retrospective chart review was performed on all thyroid FNAC specimens, corresponding molecular testing, and subsequent surgical resection specimens over a 6‐year period.Results: A total of 10,253 thyroid FNAC were performed in our hospital system during our study period, of which 10% (n = 1102/10,253) had indeterminate FNAC results. Molecular testing was performed in 16% (n = 178/1102) of indeterminate cytology cases. Genetic alterations were identified in 39% (n = 69/178) of the cases sent for molecular testing. The majority of cytologically indeterminate cases sent for molecular testing were follicular‐patterned lesions and their corresponding resection specimens revealed mostly low grade follicular derived neoplasms (i.e., follicular adenoma, non‐invasive follicular thyroid neoplasm with papillary‐like nuclear features, and follicular variant of papillary thyroid carcinoma). Of the cases with identified genetic alterations, 75% (n = 52/69) were treated surgically. In cases with no genetic alterations identified, only 18% (n = 20/109) were treated surgically.Discussion/Conclusion: Molecular testing on cytologically indeterminate thyroid nodules can help provide a more accurate risk of malignancy assessment in patients with lesions that are difficult to diagnosis based solely on FNAC morphology. The types of genetic alterations identified in the resected thyroid lesions were consistent with what has been previously described in the literature. Additionally, we found that in the patients with indeterminate thyroid FNAC with adjunct molecular testing, more than half did not undergo surgical resection. This finding emphasizes the value of adding molecular testing in patients, particularly when attempting to reduce unnecessary surgical intervention.
- 5 May 2023
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 12 (6) , 395-406
One procedure—one report: the Re-Imagine Cytopathology Task Force position paper on small tissue biopsy triage in anatomic pathology
- 5 May 2023
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 12 (6) , 395-406
One procedure—one report: the Re-Imagine Cytopathology Task Force position paper on small tissue biopsy triage in anatomic pathology
- Open Access
- 8 June 2022
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 11 (5) , 313-319
Assessing the quality of cytopathology whole slide imaging for education from archived cases
- 8 June 2022
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 11 (5) , 313-319
Open AccessAssessing the quality of cytopathology whole slide imaging for education from archived cases